South Korea
· Delayed Price · Currency is KRW Genexine Statistics
Total Valuation
Genexine has a market cap or net worth of KRW 257.40 billion. The enterprise value is 273.57 billion.
| Market Cap | 257.40B |
| Enterprise Value | 273.57B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Genexine has 41.45 million shares outstanding. The number of shares has increased by 21.23% in one year.
| Shares Outstanding | 41.45M |
| Shares Change (YoY) | +21.23% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 5.90% |
| Owned by Institutions (%) | 6.08% |
| Float | 32.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 44.15 |
| PB Ratio | 0.89 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.02 |
| EV / Sales | 47.10 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -6.47 |
Financial Position
The company has a current ratio of 1.29, with a Debt / Equity ratio of 23.84.
| Current Ratio | 1.29 |
| Quick Ratio | 1.05 |
| Debt / Equity | 23.84 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.62 |
| Interest Coverage | -11.39 |
Financial Efficiency
Return on equity (ROE) is -17.31% and return on invested capital (ROIC) is -6.98%.
| Return on Equity (ROE) | -17.31% |
| Return on Assets (ROA) | -6.70% |
| Return on Capital (ROIC) | -6.98% |
| Revenue Per Employee | 67.53M |
| Profits Per Employee | -634.02M |
| Employee Count | 86 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -38.12% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -38.12% |
| 50-Day Moving Average | 6,902.80 |
| 200-Day Moving Average | 7,937.20 |
| Relative Strength Index (RSI) | 41.86 |
| Average Volume (20 Days) | 136,784 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genexine had revenue of KRW 5.81 billion and -54.53 billion in losses. Loss per share was -1,320.62.
| Revenue | 5.81B |
| Gross Profit | -196.75M |
| Operating Income | -43.18B |
| Pretax Income | -54.51B |
| Net Income | -54.53B |
| EBITDA | -38.14B |
| EBIT | -43.18B |
| Loss Per Share | -1,320.62 |
Balance Sheet
The company has 52.50 billion in cash and 68.67 billion in debt, giving a net cash position of -16.16 billion or -389.98 per share.
| Cash & Cash Equivalents | 52.50B |
| Total Debt | 68.67B |
| Net Cash | -16.16B |
| Net Cash Per Share | -389.98 |
| Equity (Book Value) | 288.07B |
| Book Value Per Share | 6,949.76 |
| Working Capital | 14.87B |
Cash Flow
In the last 12 months, operating cash flow was -34.02 billion and capital expenditures -8.28 billion, giving a free cash flow of -42.30 billion.
| Operating Cash Flow | -34.02B |
| Capital Expenditures | -8.28B |
| Free Cash Flow | -42.30B |
| FCF Per Share | -1,020.58 |
Margins
| Gross Margin | -3.39% |
| Operating Margin | -743.54% |
| Pretax Margin | -938.51% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -728.36% |
Dividends & Yields
Genexine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.23% |
| Shareholder Yield | -21.23% |
| Earnings Yield | -21.27% |
| FCF Yield | -16.43% |
Stock Splits
The last stock split was on January 11, 2023. It was a forward split with a ratio of 1.3.
| Last Split Date | Jan 11, 2023 |
| Split Type | Forward |
| Split Ratio | 1.3 |